Next Article in Journal
A Snapshot of Transdermal and Topical Drug Delivery Research in Canada
Next Article in Special Issue
Characterization of a Reservoir-Style Implant for Sustained Release of Tenofovir Alafenamide (TAF) for HIV Pre-Exposure Prophylaxis (PrEP)
Previous Article in Journal
Investigation of Fugitive Aerosols Released into the Environment during High-Flow Therapy
Previous Article in Special Issue
Reverse Transcriptase Inhibitors Nanosystems Designed for Drug Stability and Controlled Delivery
Open AccessReview

Eradication of Human Immunodeficiency Virus Type-1 (HIV-1)-Infected Cells

Department of Biomedical Sciences, Arthur A. Dugoni School of Dentistry, University of the Pacific, 155 Fifth Street, Room 412, San Francisco, CA 94103, USA
*
Author to whom correspondence should be addressed.
Pharmaceutics 2019, 11(6), 255; https://doi.org/10.3390/pharmaceutics11060255
Received: 12 March 2019 / Revised: 1 May 2019 / Accepted: 24 May 2019 / Published: 1 June 2019
(This article belongs to the Special Issue Novel Approaches for Delivery of Anti-HIV Drugs)
Predictions made soon after the introduction of human immunodeficiency virus type-1 (HIV-1) protease inhibitors about potentially eradicating the cellular reservoirs of HIV-1 in infected individuals were too optimistic. The ability of the HIV-1 genome to remain in the chromosomes of resting CD4+ T cells and macrophages without being expressed (HIV-1 latency) has prompted studies to activate the cells in the hopes that the immune system can recognize and clear these cells. The absence of natural clearance of latently infected cells has led to the recognition that additional interventions are necessary. Here, we review the potential of utilizing suicide gene therapy to kill infected cells, excising the chromosome-integrated HIV-1 DNA, and targeting cytotoxic liposomes to latency-reversed HIV-1-infected cells. View Full-Text
Keywords: suicide gene therapy; CRISPR/Cas9; broadly neutralizing antibodies; cytotoxic liposomes; lentivirus suicide gene therapy; CRISPR/Cas9; broadly neutralizing antibodies; cytotoxic liposomes; lentivirus
Show Figures

Figure 1

MDPI and ACS Style

Düzgüneş, N.; Konopka, K. Eradication of Human Immunodeficiency Virus Type-1 (HIV-1)-Infected Cells. Pharmaceutics 2019, 11, 255.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop